targeting cldn18.2 with zolbetuximab in gastric and gej cancer
Published 1 year ago • 941 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:49
spotlight: zolbetuximab and m-folfox6 in cldn18.2 , her2- gej cancer
-
1:35
assessing the prevalence of cldn18.2 in gastric/gastroesophageal cancers
-
2:17
claudin 18.2 and fgfr2b as novel targets in gastric cancer
-
1:07
claudin 18.2: a biomarker for gastric cancer
-
0:51
claudin 18.2 as an emerging target in gastrointestinal cancers
-
2:56
will zolbetuximab impact the treatment landscape for gastric cancer?
-
1:52
iilustro: zolbetuximab, mfolfox6, and nivolumab combinations for gastrointestinal cancer
-
1:44
what role will zolbetuximab play in treating gastric cancer?
-
0:58
lb1908: a novel car-t cell therapy targeting claudin 18.2 in gi malignancies
-
0:54
targeted treatment for gastric cancer beyond her2
-
2:16
safety and efficacy of a cldn18.2-specific car t-cell therapy in gi adenocarcinoma
-
3:34
flow spotlight: addressing nausea vomiting in gastric cancer treatment with 1l zolbetuximab
-
8:41
fast: a phase iii trial of an anti-cldn18.2 antibody gej adenocarcinoma
-
7:46
results from the phase 2 fast study of astellas’ investigational zolbetuximab
-
3:03
targeted therapies for gastroesophageal adenocarcinoma
-
1:28
highlights in gastric and colorectal cancer at asco gi 2023
-
2:01
salvage ct041 cldn18.2-specific car t-cell therapy for patients with advanced gi malignancies
-
2:09
recent advances in gastrointestinal research: destiny-gastric01 and spotlight
-
0:35
gastrointestinal cancer trials to watch out for in 2023